Health and Fitness Health and Fitness
Mon, November 29, 2010
Thu, November 25, 2010
Wed, November 24, 2010
Tue, November 23, 2010
Mon, November 22, 2010
Sat, November 20, 2010
Fri, November 19, 2010
Thu, November 18, 2010
Wed, November 17, 2010
Tue, November 16, 2010
Mon, November 15, 2010
Sun, November 14, 2010
Fri, November 12, 2010
Thu, November 11, 2010
Wed, November 10, 2010
Tue, November 9, 2010
Mon, November 8, 2010
Sun, November 7, 2010
Sat, November 6, 2010
Fri, November 5, 2010

SuperGen Pipeline Presentations at EORTC-NCI-AACR


//health-fitness.news-articles.net/content/2010/ .. en-pipeline-presentations-at-eortc-nci-aacr.html
Published in Health and Fitness on Monday, November 15th 2010 at 4:45 GMT by Market Wire   Print publication without navigation


DUBLIN, Calif.--([ BUSINESS WIRE ])--SuperGen, Inc. (Nasdaq:SUPG), a pharmaceutical company dedicated to the discovery and development of novel cancer therapies, today announced the acceptance of three abstracts detailing recent work with SuperGen compounds. Poster presentations by SuperGen and collaborators will occur on November 17 and 19, 2010 at the 2010 EORTC-NCI-AACR International Symposium on Molecular Targets and Cancer Therapeutics in Berlin, Germany.

The presentations will review pre-clinical advances in amuvatinib (MP-470) and SGI-110. The posters will be made available for viewing on the companya™s website [ www.supergen.com ] following the respective presentations.

amuvatinib (MP-470): Amuvatinib (MP-470), a multi-targeted tyrosine kinase inhibitor and DNA repair suppressor, synergizes with Etoposide (VP-16) in Small Cell Lung Cancer (SCLC) cell lines and xenografts
Abstract 171, Poster 128
Poster Presentation: Wednesday Nov 17, 12:00 a" 2:20 pm CET

amuvatinib (MP-470): Effects of combining amuvatinib (MP-470) with DNA-damaging agents in osteosarcoma cell lines
Abstract 193, Poster 150
Poster Presentation: Wednesday Nov 17, 12:00 a" 2:20 pm CET

SGI-110: Immunomodulatory activity of SGI-110, a 5-aza-2a™deoxycytidine-containing demethylating dinucleotide
Abstract 547, Poster 083
Poster Presentation: Friday Nov 19, 8:00 a" 9:30 am CET

About SuperGen

SuperGen is a pharmaceutical company dedicated to the discovery and development of novel cancer therapeutics in epigenetic and cell signaling modulation. The Company develops products through biochemical and clinical proof of concept to partner for further development and commercialization. For more information about SuperGen, please visit [ http://www.supergen.com ].


Publication Contributing Sources